SMARCB1-DEFICIENT MALIGNANCIES

Clinical trials for SMARCB1-DEFICIENT MALIGNANCIES explained in plain language.

Never miss a new study

Get alerted when new SMARCB1-DEFICIENT MALIGNANCIES trials appear

Sign up with your email to follow new studies for SMARCB1-DEFICIENT MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare, Tough-to-Treat cancers in clinical trial

Disease control Recruiting now

This study is testing whether a new drug called ubamatamab, given alone or combined with an existing drug (cemiplimab), can help control two rare and aggressive cancers: renal medullary carcinoma and epithelioid sarcoma. It is for adults whose cancer has worsened after at least o…

Matched conditions: SMARCB1-DEFICIENT MALIGNANCIES

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

SMARCB1-DEFICIENT MALIGNANCIES

Get alerted when new SMARCB1-DEFICIENT MALIGNANCIES trials appear

New hope for rare, Tough-to-Treat cancers in clinical trial